Health Care·Biotechnology·$28.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.86 | N/A | -19.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.86 | N/A | -19.00% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced during the quarter. They emphasized their commitment to pipeline development, despite not providing specific guidance.
We are navigating a challenging environment.
Our focus remains on advancing our pipeline despite current setbacks.
The earnings report indicates that Revolution Medicines faced challenges, particularly reflected in their EPS miss. The stock reacted negatively, dropping 1.52%, likely due to the lack of revenue data and absence of guidance. Investors may be cautious as the company navigates its current environment and focuses on its pipeline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DIAMONDBACK ENERGY I
Feb 23, 2026